Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
COPENHAGEN, Denmark; January 3, 2023 –Genmab A/S (Nasdaq:GMAB) – In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) made by managerial employees and their closely associated persons.
The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to publish trading in Genmab shares by the company’s managerial employees and their closely associated persons.
This company announcement includes the partial vesting and net settlement of the restricted stock units granted to Jan van de Winkel and Judith Klimovsky on December 5, 2019. The remaining part of these two grants is subject to an additional vesting criteria and will vest upon confirmation thereof.
Genmab is an international biotechnology company with a core purpose guiding its unstoppable team to strive towards improving the lives of patients through innovative and differentiated antibody therapeutics. For more than 20 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational research and data sciences, which has resulted in a proprietary pipeline including bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates. To help develop and deliver novel antibody therapies to patients, Genmab has formed 20+ strategic partnerships with biotechnology and pharmaceutical companies. By 2030, Genmab’s vision is to transform the lives of people with cancer and other serious diseases with Knock-Your-Socks-Off (KYSO) antibody medicines.
Established in 1999, Genmab is headquartered in Copenhagen, Denmark with locations in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan. For more information, please visit Genmab.com and follow us on Twitter.com/Genmab.
Marisol Peron, Senior Vice President, Communications and Corporate Affairs
T: +1 609 524 0065; E: email@example.com
Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: firstname.lastname@example.org
The Company Announcement contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.comand the risk factors included in Genmab’s most recent Annual Report on Form 20-Fand other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov.Genmab does not undertake any obligation to update or revise forward looking statements in the Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.
Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; DuoBody in combination with the DuoBody logo®; HexaBody®;HexaBody in combination withthe HexaBody logo®; DuoHexaBody® and HexElect®.
CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122
Kalvebod Brygge 43
1560 Copenhagen V
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Capital structure strengthened30.1.2023 15:38:49 CET | Press release
Copenhagen, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Announcement no. 01-2023 Inside Information/Capital increase The media intelligence technology company Hypefactors, providing users with a real-time overview to reputation and trust metrics for companies, brands, competitors, industries, and trends, is pleased to announce actions which are strengthening the capital structure. A small group of investors have invested DKK 1.0 million. The share price for the capital increase is DKK 3.278, which is a ten days closing price average minus a 10% discount. As the investment is structured as a capital increase, it benefits the company’s capital structure directly. The total number of new shares to be issued is 305,064 increasing the total number of shares from 11,138,664 to 11,443,728. Furthermore, a loan facility of DKK 1 million has been established and also previously announced loan tranches of DKK 2 million from Vaekstfonden (the Danish state’s investment fund) are up for release. These financi
Alation’s Data Intelligence Project Goes Global with New Cohort of Universities30.1.2023 15:00:00 CET | Press release
Program supports the next generation of data leaders; provides hundreds of students with Alation and real-world experience REDWOOD CITY, Calif., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Alation Inc., the leader in enterprise data intelligence solutions, announced three new universities participating in its philanthropic initiative, The Data Intelligence Project. New universities include The University of Arkansas at Little Rock in Arkansas, The University of Cincinnati in Ohio, and The University of Stirling in Scotland. More than 420 students have used Alation in their courses to date, with this year’s global cohort providing real-world experience to hundreds of new students via Alation. The Data Intelligence Project, launched in 2021, builds a more data-literate, curious, and rational world by nurturing the next generation of data professionals. As part of The Data Intelligence Project, Alation brings its data intelligence platform, free of charge, into academic institutions and provides un
Fortinet Expands its Services and Training Offerings to Further Support SOC Teams in Preventing and Defending Against Cyber Threats30.1.2023 15:00:00 CET | Press release
Multi-Faceted Approach Accelerates Fortinet’s Global Commitment to Eliminate the Cybersecurity Skills Gap SUNNYVALE, Calif., Jan. 30, 2023 (GLOBE NEWSWIRE) -- John Maddison, EVP of Products and CMO at Fortinet “Fortinet builds ML-driven automation into all of its SOC offerings to support short-staffed teams affected by the cybersecurity skills shortage. But technology alone won’t solve this issue, which is why we are dedicated to also delivering human-based SOC augmentation services to provide immediate support, while investing in an industry-leading training institute to close the cybersecurity skills gap. This combination of technology, services, and training enables SOC professionals to better protect their organizations from detection to incident recovery.” News Summary Fortinet® (NASDAQ: FTNT), a global leader in broad, integrated, and automated cybersecurity solutions, today announced new security operations center (SOC) augmentation services designed to help strengthen an organi
Cozycozy is the Only Accommodation Search Engine That Now Includes Airbnb, Giving Travelers the Largest Selection of Vacation Rentals Possible30.1.2023 14:30:00 CET | Press release
One search, so many possibilities - cozycozy helps users find their perfect holiday accommodation from over 100+ booking platforms, including Airbnb. NEW YORK, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Cozycozy knows that finding the perfect place to stay can be hard. With the rise of so many vacation rental and hotel platforms comes more and more options, overwhelming travelers. "The days of having multiple tabs open to find the best deal are over," says Romain Claudel, co-founder of cozycozy. "We created cozycozy.com so travelers can see all their options in one place, without all the hassle." There are more and more vacation rentals and hotel rooms listed on several platforms, often with rates that vary. By using cozycozy, users conveniently get the lowest price possible. Their website allows users to see a comprehensive list of available options all at once, so that they get the best rates. They are the only platform in the world to include Airbnb in its search engines, letting users compa
Bank of Åland Plc: Managers' Transactions (Johansson)30.1.2023 14:30:00 CET | Press release
Bank of Åland Plc Managers' Transactions January 30, 2023, 15.30 EET Managers' Transactions --- Person subject to the notification requirement Name: Magnus Johannsson Position: Other senior manager Issuer: Ålandsbanken Abp LEI: 7437006WYM821IJ3MN73 Notification type: INITIAL NOTIFICATION Reference number: 24871/4/4 --- Transaction date: 2023-01-25 Outside a trading venue Instrument type: SHARE ISIN: FI0009001127 Nature of transaction: SUBSCRIPTION Transaction details (1): Volume: 233 Unit price: 32.98 EUR Aggregated transactions (1): Volume: 233 Volume weighted average price: 32.98 EUR For further information, please contact: Peter Wiklöf, Managing Director and Chief Executive, tel +358 40 512 7505